A cohort study of acute pancreatitis in relation to exenatide use

Diabetes, Obesity and Metabolism

Volumn 13, Issue 6, 2011, Pages 559-566

  Dore, D D ^a,b   Bloomgren, G L ^c   Wenten, M ^c   Hoffman, C ^a   Clifford, C R ^a   Quinn, S G ^a   Braun, D K ^d   Noel, R A ^d   Seeger, J D ^a,e,f  

^a i3 Drug Safety   (United States)

^b BROWN UNIVERSITY   (United States)

^c BIOGEN   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adverse drug reactions; Antidiabetic drug; Exenatide; Incretin therapy; Pharmacoepidemiology

Indexed keywords

EXENDIN 4; HYPERGLYCEMIC AGENT;

ACUTE PANCREATITIS; ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; POISSON DISTRIBUTION; PROPENSITY SCORE; REGRESSION ANALYSIS;

EID: 79954994764     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01376.x     Document Type: Article

References (34)

1. BYETTA Prescribing Information. Available from URL: Accessed 5 February 2010.
2. Barnett AH, Burger J, Johns D et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007; 29: 2333-2348.
3. Cure P, Pileggi A, Alejandro R et al. Exenatide and rare adverse events. N Engl J Med 2008; 358: 1969-1972.
4. Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006; 29: 471.
5. Food and Drug Administration MedWatch. 2007 safety alerts for human medical products. Updated 9 June 2009. Available from URL: Accessed 28 February 2011.
6. US Food and Drug Administration MedWatch. BYETTA (exenatide) injection-detailed view: safety labeling changes approved by FDA center for drug evaluation and research (CDER)-October 2009. Available from URL: Accessed 5 February 2010.
7. Butler AE, Galasso R, Matveyenko A, Rizza RA, Dry S, Butler PC. Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia 2010; 53: 21-26.
8. Butler PC, Dry S, Elashoff R. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care 2010; 33: 453-455.
9. Butler PC, Matveyenko AV, Dry S, Bhushan A, Elashoff R. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia 2010; 53: 1-6.
10. Matveyenko AV, Dry S, Cox HI et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes interactions with metformin. Diabetes 2009; 58: 1604-1615.
11. Nachnani JS, Bulchandani DG, Nookala A et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010; 53: 153-159.
12. Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like-peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009; 58: 2148-2161.
13. United States Food and Drug Administration (FDA). Byetta Risk Evaluation and Mitigation Strategy (REMS). Available from URL: Accessed 28 February 2011.
14. Tatarkiewicz K, Smith P, Sablan EJ et al. Exenatide does not evoke pancreatitis and attenuates chemically-induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 2010; 299: E1076-1086.
15. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective, cohort study. Diabetes Care 2009; 32: 834-838.
16. Crystal S, Akincigil A, Bilder S, Walkup JT. Studying prescription drug use and outcomes with medicaid claims data: strengths, limitations, and strategies. Med Care 2007; 45: S58-65.
17. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 1989; 129: 837-849.
18. Walker AM. Pattern recognition in health insurance claims databases. Pharmacoepidemiol Drug Saf 2001; 10: 393-397.
19. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-920.
20. Carroll JK, Herrick B, Gipson T, Lee SP. Acute pancreatitis: diagnosis, prognosis, and treatment. Am Fam Physician 2007; 75: 1513-1520.
21. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009; 20: 512-522.
22. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999; 8: 3-15.
23. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: J. Wiley & Sons, 1987.
24. Dore DD, Seeger JD, Chan KA. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25: 1019-1027.
25. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther 1998; 20: C40.
26. Sachs RM, Bortnichak EA. An evaluation of spontaneous adverse drug reaction monitoring systems. Am J Med 1986; 81: 49-55.
27. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP, eds. Advances in Inflammation Research, Vol. 6. New York: Raven Press, 1984.
28. Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. Lancet 2008; 371: 143-152.
29. Rodgers A, MacMahon S. Systematic underestimation of treatment effects as a result of diagnostic test inaccuracy: implications for the interpretation and design of thromboprophylaxis trials. Thromb Haemost 1995; 73: 167-171.
30. Blomgren KB, Sundstrom A, Steineck G, Wiholm BE. Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. Diabetes Care 2002; 25: 298-302.
31. Sandzen B, Rosenmuller M, Haapamaki M, Nilsson E, Stenlund H, Oman M. First attack of acute pancreatitis in Sweden 1988 - 2003: incidence, aetiological classification, procedures and mortality - a register study. BMC Gastroenterol 2009; 9: 18.
32. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Weight cycling and risk of gallstone disease in men. Arch Intern Med 2006; 166: 2369-2374.
33. McKenzie DA, Semradek J, McFarland BH, Mullooly JP, McCamant LE. The validity of Medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol 2000; 53: 1248-1257.
34. Tenner and Steinberg. Drug-Induced Pancreatitis. In: Beger HG, Warshaw AL, Sarr MG et al., eds. The Pancreas, Vol. 2. Oxford, UK: Wiley-Blackwell, 1998; 331-342.